

K080271

510(k) Summary

superDimension, Ltd.  
Traditional 510(k)  
Indication Expansion

MAR 31 2008

**Date Prepared:**

01/31/2008

**510(k) Applicant:**

superDimension, Ltd.  
8 Hamenofim St., P.O. Box 2045  
Herzliya 46120  
Israel  
Ph: +972-(0)9-971-3700  
Fax: +972-(0)9-971-3701

**510(k) Application Correspondent:**

Jonathan Kovach  
Vice President, Quality and Regulatory Affairs  
superDimension, Inc.  
161 Cheshire Lane, Suite 100  
Minneapolis, MN 55441  
Phone: 763-210-4015  
Cell : 763-360-4984  
Fax : 763-210-4098  
Email : [jkovach@superdimension.com](mailto:jkovach@superdimension.com)

**Name of Device :**

Trade Name : - superDimension®/Bronchus  
- inReach™ System  
Common Name: Bronchoscope  
Classification Name: Computed tomography x-ray system  
21 CFR Part 892.1750  
Product code JAK

**Equivalent Legally-Marketed Device:**

superDimension/Bronchus Premium 2, K071473

**Description:**

The superDimension/Bronchus System is a device that guides a bronchoscope and bronchial tool to a target in or adjacent to the bronchial tree on a path indicated by CT scan, and visualizes the target and the interior of the tree. The superDimension/Bronchus also enables the placement of radiosurgical and dye markers into soft lung tissue to guide radiosurgery and thoracic surgery.

**Intended Use:**

Indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tools or catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool. Not for pediatric use.

**Summary of Characteristics Compared to Predicate Device:**

Changes are being made to the Instructions for Use to include guidance and instruction for deploying radiosurgical and dye markers into soft lung tissue with the superDimension/Bronchus System.

No changes are being made to the hardware or software design, or technological characteristics of the current marketed device.

**Performance Data:**

The changes to the Instructions for Use were subjected to the superDimension design control process. A hazard analysis was performed to analyze the potential hazards associated with the changes. Appropriate design validations were performed to assure the superDimension/Bronchus continues to meet the expanded user needs and intended uses.

**Clinical Data:**

Clinical tests were not required to validate the changes to the superDimension/Bronchus System. **Multiple published studies have demonstrated the Bronchus is safe and effective when used to place radiosurgical and dye markers into soft lung tissue to guide radiosurgery and thoracic surgery.**

**Conclusion:**

The superDimension/Bronchus is safe and effective for its intended use.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
9200 Corporate Blvd.  
Rockville MD 20850

superDimension, Ltd.  
% Mr. Jonathan Kovach  
Vice President, Quality and Regulatory Affairs  
superDimention, Incorporated  
161 Cheshire Lane, Suite 100  
MINNEAPOLIS MN 55441

**MAR 31 2008**

Re: K080271  
Trade/Device Name: superDimension@/Bronchus  
inReach™ System  
Regulation Number: 21 CFR 892.1750  
Regulation Name: Computed tomography x-ray system  
Regulatory Class: II  
Product Code: JAK  
Dated: January 31, 2008  
Received: February 1, 2008

Dear Mr. Kovach:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.



*Protecting and Promoting Public Health*

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K080271

Device Name: superDimension/Bronchus

Indications for Use:

Indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tools or catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool.

Not for pediatric use.

Prescription Use   X    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K080271

Page \_\_\_ of \_\_\_